OR WAIT null SECS
GenScript’s new gene synthesis center in Piscataway, NJ, is highly automated to accelerate production time and increase supply chain resiliency for biopharma and synthetic biology.
GenScript USA, a life science research tools and services provider, announced on Nov. 2, 2021 that it opened a new highly automated facility for gene synthesis and plasmid preparation services in Piscataway, NJ. The new larger-than-50,000-ft2 facility expands the company's advanced gene synthesis services and is designed to mitigate supply chain risks in the United States for new vaccines, therapeutics, and innovations in synthetic biology. The new facility is GenScript's first automated manufacturing site in the US and represents a 10-fold increase in capacity.
"GenScript is extremely committed to supporting our customers as they expand globally, and this specialized laboratory and manufacturing facility allows us to deliver reliable products to them faster than ever before," said Ray Chen, president of GenScript USA Life Science Group, in a company press release. "Importantly, this site also gives our US customers additional production resilience in case of unexpected events, such as pandemics and changes in customs and trade regulations."
"We are fortunate to be located in an area where this in an abundance of talent and expertise," Chen added. "With this facility, we also intend to add 100–200 jobs in research and manufacturing over the next two years."